Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Danaher Corporation (NYSE: DHR) announced that CEO Rainer M. Blair will present the fourth quarter 2022 financial performance at the J.P. Morgan Healthcare Conference on January 10, 2023. Estimated revenues are expected to rise in the low-single digits year-over-year, with non-GAAP core revenue growth projected in the high-single digits, exceeding previous guidance. Cepheid's molecular diagnostics business has notably contributed over $1 billion in respiratory testing revenues in the quarter. Danaher is optimistic about sustaining long-term shareholder value.
Danaher Corporation (NYSE: DHR) announced that its President and CEO, Rainer M. Blair, will present at the J.P. Morgan Healthcare Conference on January 10, 2023, at 4:30 p.m. ET. The presentation will be available via a webcast and archived on Danaher’s website. Danaher is a leading global science and technology innovator focused on solving complex challenges in healthcare and environmental markets. With a team of around 80,000 associates, Danaher operates more than 20 companies under its comprehensive business system.
Danaher Corporation (NYSE: DHR) has scheduled a webcast for its fourth quarter 2022 earnings conference call on January 24, 2023, at 8:00 a.m. ET. The duration is expected to be around one hour, during which the company will discuss its financial performance and future expectations. Presentations will be available on their website, and a replay will be accessible shortly after the call. Investors can join by dialing in, and additional details will be provided in the Investors section of Danaher’s website.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.25 per share for common stock, payable on January 27, 2023, to holders of record on December 30, 2022. Additionally, a cash dividend of $12.50 per share on its 5.00% Series B Mandatory Convertible Preferred Stock will be paid on January 15, 2023, to those on record as of December 31, 2022. This dividend announcement underscores Danaher's commitment to returning value to shareholders.
Danaher Corporation (NYSE: DHR) has announced that its President and CEO, Rainer M. Blair, will present at the Evercore ISI HealthCONx Conference on November 30, 2022, at 10:30 a.m. ET. The presentation will be available via a live webcast on their official website, www.danaher.com.
As a leader in science and technology, Danaher aims to resolve complex challenges while enhancing global quality of life through its innovative solutions.
Cepheid has launched the Xpert Xpress MVP, an FDA-cleared multiplex PCR test that identifies DNA from organisms responsible for bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis from a single sample within an hour. This innovation addresses the 10 million annual healthcare visits related to vaginitis in the U.S., enabling more accurate diagnoses and effective treatments while reducing treatment failures and antimicrobial resistance. The test expedites diagnosis, ultimately enhancing patient outcomes in women's health.
Danaher Corporation (NYSE: DHR) has announced a strategic partnership with Duke University to create the first Danaher Beacon for Gene Therapy Innovation. This initiative aims to leverage breakthrough science for advancements in genomic medicines, precision diagnostics, and biomanufacturing. Dr. Aravind Asokan from Duke will lead the project, focusing on improving viral vector manufacturing. The collaboration, which commenced in late October 2022, is set to extend over several years, emphasizing the importance of academic partnerships in driving innovation in gene therapy.
Danaher Corporation (NYSE: DHR) reported strong Q3 2022 results with net earnings of $1.6 billion, or $2.10 per diluted share, marking a 36% increase year-over-year. Revenues rose 6% to $7.7 billion, while non-GAAP adjusted diluted earnings per share increased 7% to $2.56. The company saw a solid 10% growth in non-GAAP core revenues. Operating cash flow was $2 billion, and free cash flow reached $1.7 billion. Looking ahead, Danaher expects high-single digit growth in non-GAAP core revenue for Q4 and the full year 2022.
Danaher Corporation (NYSE: DHR) has scheduled its third quarter 2022 earnings conference call for October 20, 2022, at 8:00 a.m. ET. This one-hour call will be accessible via webcast on Danaher's website under the Investors section. A slide presentation will accompany the call, and a replay will be available until November 3, 2022. The earnings press release and related materials will be posted at 6:00 a.m. ET on the same day.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
